Plant ID: NPO26741
Plant Latin Name: Anemarrhena asphodeloides
Taxonomy Genus: Anemarrhena
Taxonomy Family: Asparagaceae
NCBI TaxonomyDB:
59045
Plant-of-the-World-Online:
530140-1
Antianxiety; Antifungal; Antiseptic; Bitter; Diuretic; Expectorant; Febrifuge; Hypoglycaemic; Laxative; Lenitive; Sedative; Tonic
India; Taiwan; China; Mongolia; South Africa
TSHR; | |
HCAR2; | |
PDE5A; | |
GAA; | |
BLM; IDO1; AKR1B1; HSD17B10; ALOX15; | |
PIM1; CSNK2A1; | |
CA12; CA1; CA5B; CA5A; CA6; | |
PPARA; PPARD; | |
ESR1; ESR2; | |
MAOB; | |
BACE1; | |
TLR2; | |
HIF1A; | |
ABCB1; | |
SLCO1B3; SLCO1B1; | |
LMNA; FABP3; FABP5; FABP2; FABP4; MAPT; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | IDO1 | Indoleamine 2,3-dioxygenase | P14902 | CHEMBL4685 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Oxidoreductase | MAOB | Monoamine oxidase B | P27338 | CHEMBL2039 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Phosphodiesterase 5 | PDE5A | Phosphodiesterase 5A | O76074 | CHEMBL1827 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
Small molecule receptor (family A GPCR) | HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 | CHEMBL3785 |
Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.988E-11 | 5.430E-07 | CA1, CA12, CA5A, CA5B, CA6 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 6.088E-09 | 1.894E-05 | CA1, CA12, CA5A, CA5B, CA6 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.735E-08 | 4.198E-05 | CA1, CA12, CA5A, CA5B, CA6 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.184E-07 | 1.996E-04 | CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.250E-07 | 1.996E-04 | FABP2, FABP3, FABP4, FABP5 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.293E-06 | 1.173E-03 | CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.549E-06 | 1.298E-03 | BLM, CA1, CA12, CA5A, CA5B, CA6, ESR1, ESR2, PPARA, PPARD |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 3.377E-06 | 2.372E-03 | ESR1, ESR2 |
BP | GO:0051179; localization | GO:0015718; monocarboxylic acid transport | 4.392E-06 | 2.813E-03 | FABP3, PPARA, PPARD, SLCO1B1, SLCO1B3 |
BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 5.811E-06 | 3.615E-03 | AKR1B1, CYP2C19, CYP2C9, CYP3A4, ESR1, PPARD |
BP | GO:0051179; localization | GO:0006869; lipid transport | 9.068E-06 | 5.063E-03 | ABCB1, FABP3, PPARA, PPARD, SLCO1B1, SLCO1B3 |
BP | GO:0008152; metabolic process | GO:0006631; fatty acid metabolic process | 1.628E-05 | 7.751E-03 | ALOX15, CYP2C19, CYP2C9, FABP3, PPARA, PPARD |
BP | GO:0032501; multicellular organismal process | GO:0001816; cytokine production | 1.681E-05 | 7.789E-03 | FABP4, HIF1A, IDO1, TLR2 |
BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 1.731E-05 | 7.852E-03 | ESR1, ESR2, PIM1, PPARA, PPARD |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 2.022E-05 | 8.322E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.022E-05 | 8.322E-03 | CYP2C9, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 2.308E-05 | 8.975E-03 | AKR1B1, CSNK2A1, ESR1, FABP3, MAOB, PPARA, TLR2, TSHR |
BP | GO:0008283; cell proliferation | GO:0042127; regulation of cell proliferation | 2.419E-05 | 9.239E-03 | AKR1B1, CSNK2A1, ESR1, FABP3, HIF1A, IDO1, LMNA, PDE5A, PIM1, PPARD, TLR2, TSHR |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 8.618E-11 | 7.670E-09 | CA12, CA1, CA5B, CA5A, CA6 |
09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 2.424E-09 | 1.079E-07 | FABP2, FABP3, FABP4, FABP5, PPARA, PPARD |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 2.033E-07 | 6.031E-06 | CYP2C9, ALOX15, CYP3A4, CYP2C19 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 7.031E-06 | 1.403E-04 | CYP2C9, MAOB, CYP3A4, CYP2C19 |
09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 7.882E-06 | 1.403E-04 | SLCO1B1, ABCB1, SLCO1B3, CYP3A4 |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 4.781E-05 | 7.091E-04 | CYP2C9, MAOB, ALOX15, CYP2C19 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 2.677E-04 | 2.978E-03 | CYP2C9, MAOB, GAA, ALOX15, AKR1B1, CYP2C19, CYP3A4, HSD17B10, IDO1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 1.883E-04 | 2.394E-03 | CYP2C9, ALOX15, CYP2C19 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 4.302E-04 | 4.254E-03 | CYP2C9, CYP3A4, CYP2C19 |
09100 Metabolism | 09101 Carbohydrate metabolism | hsa00052 | Galactose metabolism | 1.328E-03 | 1.182E-02 | GAA, AKR1B1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | PDE5A; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | PDE5A; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | PDE5A; HCAR2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | HCAR2; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; |
NA: NA | Raynaud's disease | NA | PDE5A; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | PDE5A; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HCAR2; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PDE5A; |
I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | PDE5A; |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | HCAR2; |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | PDE5A; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | PDE5A; |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HCAR2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HCAR2; |
I00-I99: Diseases of the circulatory system | Acute ischemic stroke | I61-I63 | HCAR2; |